Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes
Annals of Pharmacotherapy · 2024
DOI: 10.1177/10600280231197255 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Pharmacotherapy, 2024. Verfasst von Rachel E Webster und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Trinity Health Grand Rapids, Grand Rapids, MI, USA. Hauptthemen laut MEDLINE: Critical Illness, Insulin, Blood Glucose, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
There is limited evidence evaluating the impact of insulin treatment strategies on glucose variability in critically ill patients without preexisting diabetes.
Objective
Compare basal plus insulin (BPI) and sliding scale insulin (SSI) impact on glycemic control outcomes in critically ill patients without preexisting diabetes experiencing hyperglycemia.
Methods
This multicenter, retrospective review analyzed critically ill patients with hyperglycemia who received either BPI or SSI. Patients with a hemoglobin A1C >6.5% during the admission of interest or in the previous 3 months, or a diagnosis of diabetes at the time of discharge were excluded. The primary outcome was glucose variability during the intensive care unit (ICU) admission. Secondary outcomes included hypoglycemia frequency, frequency of goal glucose levels, mortality, and length of stay.
Results
The analysis included 228 patients (39 in BPI, 189 in SSI). Average glucose variability was higher in the BPI group compared with the SSI group (85.8 mg/dL ± 33.1 vs 70.2 mg/dL ± 30.7; P = 0.009), which remained when controlling for baseline confounding (−12.1 [5.6], 95% CI −23.2 to −0.99; P = 0.033). Hypoglycemia incidence was similar between groups. BPI patients had a lower incidence of glucose values within goal range than SSI patients ( P = 0.046). There was no difference in length of stay or hospital mortality. Conclusions and Relevance: The use of SSI compared with a BPI regimen may result in reduced glycemic variability in critically ill patients without preexisting diabetes. Future prospective studies, with a larger sample size, are warranted to confirm our exploratory findings and characterize clinically significant benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Trinity Health Grand Rapids, Grand Rapids, MI, USA.
- College of Pharmacy, Ferris State University, Big Rapids, MI, USA.
ORCID-Profile: Julie J Belfer, Kyle J Schmidt
Zitieren
APA
Webster, R. E., Belfer, J. J., & Schmidt, K. J. (2024). Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280231197255
Vancouver
Webster RE, Belfer JJ, Schmidt KJ. Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes. Annals of Pharmacotherapy. 2024. doi:10.1177/10600280231197255
BibTeX
@article{Webster2024,
author = {Webster, Rachel E and Belfer, Julie J and Schmidt, Kyle J},
title = {Evaluation of Basal Plus Versus Sliding Scale Insulin Therapy on Glucose Variability in Critically Ill Patients Without Preexisting Diabetes},
journal = {Annals of Pharmacotherapy},
year = {2024},
doi = {10.1177/10600280231197255}
}
EUVIMED